Liminal Biosciences is a clinical stage biopharmaceutical company focused on developing distinctive small molecule therapeutics for inflammatory, fibrotic and metabolic diseases using Co.'s drug discovery platform and data-driven approach. Co.'s research and development programs are focused on inflammatory, fibrotic and metabolic conditions in patients with respiratory, liver or renal disease. Co.'s pipeline is made up of three development programs. Co.'s main asset, fezagepras (also known as PBI-4050), a clinical-stage product candidate, as a potential nitrogen scavenger and its GPR84 antagonist and OXER1 antagonist programs, which are preclinical. We show 3 historical shares outstanding datapoints in our LMNL shares outstanding history coverage, used to compute LMNL market cap on those dates.
Understanding the changing numbers of shares outstanding, the changing
share price, and the resulting changing LMNL market cap history over the course of time is important for investors
interested in comparing LMNL's market cap history versus its peers.
Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at
a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies,
and then calculating their respective market caps. Comparing the share price of LMNL versus a peer is one thing; comparing
LMNL market cap versus a peer is a completely different story.
Furthermore, via fluctuation both in per-share price and in the number of shares outstanding (via issuance of new shares over time, the repurchase of existing shares),
the market cap for a company like LMNL can fluctuate over the course of history.
With this page we aim to empower investors researching LMNL by allowing them to research the LMNL market cap history. |
Free LMNL Email Alerts:
Video: The Importance of Market Cap
